Production (Stage)
bluebird bio, Inc.
BLUE
$4.98
-$0.02-0.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 108.57% | 403.48% | -13.59% | 135.50% | 708.41% |
| Total Other Revenue | -- | -100.00% | -- | -- | -85.88% |
| Total Revenue | 108.43% | 391.72% | -14.36% | 133.69% | 680.05% |
| Cost of Revenue | -52.69% | 86.92% | 29.09% | 332.22% | 369.23% |
| Gross Profit | 463.12% | 460.99% | -135.79% | -6,755.44% | -132.86% |
| SG&A Expenses | -31.10% | -29.14% | -3.63% | 19.41% | 16.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.09% | -21.12% | -31.07% | 32.93% | 1,262.90% |
| Operating Income | 72.67% | 58.17% | 33.23% | -23.25% | -832.36% |
| Income Before Tax | 58.50% | 64.63% | 30.23% | -29.43% | -468.75% |
| Income Tax Expenses | -- | 332.61% | -- | 126.25% | -- |
| Earnings from Continuing Operations | 58.36% | 64.48% | 30.29% | -29.63% | -468.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.36% | 64.48% | 30.29% | -29.63% | -468.75% |
| EBIT | 72.67% | 58.17% | 33.23% | -23.25% | -832.36% |
| EBITDA | 90.57% | 71.18% | 44.96% | -9.49% | -473.72% |
| EPS Basic | 58.75% | 78.34% | 60.78% | 27.27% | -296.48% |
| Normalized Basic EPS | 68.83% | 78.39% | 62.55% | 27.38% | -296.48% |
| EPS Diluted | 58.77% | 78.34% | 60.80% | 27.56% | -300.83% |
| Normalized Diluted EPS | 68.83% | 78.39% | 62.55% | 27.38% | -297.21% |
| Average Basic Shares Outstanding | 0.96% | 64.00% | 77.72% | 78.23% | 87.68% |
| Average Diluted Shares Outstanding | 0.96% | 64.00% | 77.72% | 78.23% | 86.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |